COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,950 Articles (22,604 medRxiv, 8,346 bioRxiv)

Most recent first Previous |  Page 290: Articles 2891-2900  | Next

Feasibility of intranasal delivery of thin-film freeze-dried monoclonal antibodies
Yu, Y.-S., Xu, H., AboulFotouh, K., Williams, G., Suman, J., Sahakijpijarn, S., Cano, C., Warnken, Z., Wu, K. C.- W., Williams, R. O., Cui, Z.
10.1101/2023.10.23.563139 — Posted: 2023-10-24
A 50-gene high-risk profile predictive of COVID-19 and Idiopathic Pulmonary Fibrosis mortality originates from a molecular imbalance in monocyte and T-cell subsets that reverses in survivors with post-COVID-19 Interstitial Lung Disease
Tourki, B., Jia, M., Karampitsakos, T., Vera, I. M., Arsenault, A., Marlin, K., Perrot, C. Y., Allen, D., Farsaei, F., Rutenberg, D., Bandyopadhyay, D., Restrepo, R., Qureshi, M. R., Patel, K., Tzouvelekis, A., Kapetanaki, M., Juan-Guardela, B., Kim, K., Benos, P. V., Herazo-Maya, J.
10.1101/2023.10.22.563156 — Posted: 2023-10-24
Post-COVID chronic neuropsychiatric symptoms persisting beyond one year from infection- a case-control study and network analysis
Chau, S. W. H., Chue, T. M., Chan, R. N. Y., Lai, Y. L., Wong, P. W., Li, S. X., Liu, Y., Chan, J. W., Chan, P. K. S., Lai, C. K.-C., Leung, T. W., Wing, Y. K.
10.1101/2023.10.22.23297069 — Posted: 2023-10-23
Proportion of cancer cases and deaths attributable to potentially modifiable risk factors in Peru prior to the COVID-19 pandemic
De La Cruz-Vargas, J. A., Ramos, W., Chanduvi Puicon, W. D., Correa-Lopez, L. E., Guerrero, N., Loayza-Castro, J., Tami-Maury, I. M., Venegas, D.
10.1101/2023.10.22.23297358 — Posted: 2023-10-23
ASSESSING SYSTEM PERFORMANCE OF MATERNAL AND CHILD HEALTH CARE DURING COVID-19 PANDEMIC IN COMMUNITY HEALTH CENTER- COMORO DILI TIMOR-LESTE.
Soares, D., Lopes, A. A., Perreira, D. d. C., Silva, V. d., Martins, N.
10.1101/2023.10.23.23297388 — Posted: 2023-10-23
Evaluation of the neutralising antibody response in human and hamster sera against SARS-CoV-2 variants up to and including BA.2.86 using an authentic virus neutralisation assay
Coombes, N. S., Bewley, K. R., Le Duff, Y., Alami-Rahmouni, N., Ryan, K. A., Kempster, S., Ferguson, D., Davies, E. R., Weldon, T. M., Cross, E. S., Smith, L., Norris, C., Rogers-Broadway, K. R., Lewandowski, K., Treagus, S., Pullan, S. T., Hallis, B., Charlton, S., Hall, Y., Funnell, S. G. P.
10.1101/2023.10.21.563398 — Posted: 2023-10-23
Viral envelope proteins fused to multiple distinct fluorescent reporters to probe receptor binding
Tomris, I., van der Woude, R., de Paiva Droes Rocha, R., Torrents de la Pena, A., Ward, A. B., de Vries, R. P.
10.1101/2023.10.23.563555 — Posted: 2023-10-23
Assessing nanobody interaction with SARS-CoV-2 Nsp9
Esposito, G., Hunashal, Y., Percipalle, M., Fogolari, F., Venit, T., Leonchiks, A., Gunsalus, K. C., Piano, F., Percipalle, P.
10.1101/2023.10.20.563308 — Posted: 2023-10-23
Changes in total charge on spike protein of SARS-CoV-2 in emerging lineages
Bozic, A., Podgornik, R.
10.1101/2023.10.21.563433 — Posted: 2023-10-23
Screening Peptide Drug Candidates to Neutralize Whole Viral Agents : A Case study with SARS-CoV-2 Virus
Ozcelik, C. E., Araz, C. Z., Yilmaz, O., Gulyuz, S., Ozkul, A., Seker, U. O. S.
10.1101/2023.10.22.563490 — Posted: 2023-10-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).